Evidence map›Paper›PMID 35699817›Full record

ArticleNano-micro letters2022

MXene-Graphene Composites: A Perspective on Biomedical Potentials.

Ebrahim Mostafavi, Siavash Iravani

Open access · diamondAbstract read
In one paragraph

Article in Nano-micro letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. 2D-nanomaterials for AKI treatment.Frontiers in bioengineering and biotechnology · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. MXenes in Cancer Nanotheranostics.Nanomaterials (Basel, Switzerland) · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ebrahim MostafaviStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA. ebimsv@stanford.edu.ORCID https://orcid.org/0000-0003-3958-5002
Siavash IravaniFaculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. siavashira@gmail.com.ORCID https://orcid.org/0000-0003-3985-7928
Cardiovascular Institute of the South · USIsfahan University of Medical Sciences · IR

Funding

Multi-Disciplinary Training Program in Cardiovascular Imaging at StanfordT32EB009035 · NIBIB · STANFORD UNIVERSITY · PI Koen Nieman, John M. Pauly · 2008 to 2026
$4.3M
NIBIB NIH HHS T32 EB009035
6 · The paper itself

Abstract

MXenes, transition metal carbides and nitrides with graphene-like structures, have received considerable attention since their first discovery. On the other hand, Graphene has been extensively used in biomedical and medicinal applications. MXene and graphene, both as promising candidates of two-dimensional materials, have shown to possess high potential in future biomedical applications due to their unique physicochemical properties such as superior electrical conductivity, high biocompatibility, large surface area, optical and magnetic features, and extraordinary thermal and mechanical properties. These special structural, functional, and biological characteristics suggest that the hybrid/composite structure of MXene and graphene would be able to meet many unmet needs in different fields; particularly in medicine and biomedical engineering, where high-performance mechanical, electrical, thermal, magnetic, and optical requirements are necessary. However, the hybridization and surface functionalization should be further explored to obtain biocompatible composites/platforms with unique physicochemical properties, high stability, and multifunctionality. In addition, toxicological and long-term biosafety assessments and clinical translation evaluations should be given high priority in research. Although very limited studies have revealed the excellent potentials of MXene/graphene in biomedicine, the next steps should be toward the extensive research and detailed analysis in optimizing the properties and improving their functionality with a clinical and industrial outlook. Herein, different synthesis/fabrication methods and performances of MXene/graphene composites are discussed for potential biomedical applications. The potential toxicological effects of these composites on human cells and tissues are also covered, and future perspectives toward more successful translational applications are presented. The current state-of-the-art biotechnological advances in the use of MXene-Graphene composites, as well as their developmental challenges and future prospects are also deliberated. Due to the superior properties and multifunctionality of MXene-graphene composites, these hybrid structures can open up considerable new horizons in future of healthcare and medicine.

Indexed as

BiocompatibilityBiomedical engineeringCancer theranosticsCompositesGrapheneHybrid structuresMXene

Identifiers

PMID35699817
PMCPMC9195398
OpenAlexW4282821580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.